Drug intelligence / Profile preview

V3-Cervix

Development stage: Phase 2
Lead developer: Immunitor
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

V3-Cervix is an oral tableted biological preparation developed by Immunitor LLC for the treatment of cervical cancer. It is derived from hydrolyzed, inactivated blood and tumor tissues of patients with cervical cancer. When administered orally, it is designed to elicit a specific anti-tumor immune response and an anti-inflammatory effect. The drug is currently being evaluated in a Phase II clinical trial.

Beyond the preview

Go deeper on V3-Cervix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V3-Cervix.

Explore the full profile